IQVIA Holdings Inc header image

IQVIA Holdings Inc

IQV

Equity

ISIN US46266C1053 / Valor 39103858

New York Stock Exchange, Inc (2024-09-18)
USD 242.67+1.12%

IQVIA Holdings Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

IQVIA Holdings Inc is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The company's Innovation Hub facilitates collaboration between start-ups and its extensive network of assets, resources, clients, and partners to drive innovation in healthcare. Additionally, IQVIA's Human Data Science Cloud offers healthcare-grade analytics, tools, and data management solutions to deliver global data at scale. With a focus on leveraging data and technology to improve healthcare outcomes, IQVIA plays a crucial role in shaping the future of the industry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Revenue Growth

IQVIA Holdings Inc. reported revenue of $3,814 million for the second quarter of 2024, marking a 2.3 percent increase on a reported basis and a 3.5 percent increase at constant currency compared to the same quarter in 2023. This growth was driven by strong performance in the Technology & Analytics Solutions (TAS) and Research & Development Solutions (R&DS) segments.

Net Income and Earnings

For the second quarter of 2024, IQVIA Holdings Inc. achieved a GAAP Net Income of $363 million, translating to a GAAP Diluted Earnings per Share of $1.97. On an adjusted basis, the company reported an Adjusted Net Income of $487 million and an Adjusted Diluted Earnings per Share of $2.64.

Segment Performance

IQVIA Holdings Inc.'s R&DS segment reported revenue of $2,147 million for the second quarter of 2024, reflecting a 2.4 percent increase on a reported basis and a 3.3 percent increase at constant currency. The TAS segment also showed robust growth with revenue of $1,495 million, up 2.7 percent on a reported basis and 3.8 percent at constant currency.

Contracted Backlog

As of June 30, 2024, IQVIA Holdings Inc.'s R&DS contracted backlog, including reimbursed expenses, stood at $30.6 billion, representing a 7.7 percent increase year-over-year and an 8.1 percent increase at constant currency. The company expects approximately $7.8 billion of this backlog to convert to revenue within the next twelve months.

Full-Year 2024 Guidance

IQVIA Holdings Inc. updated its full-year 2024 guidance, projecting revenue to be between $15,425 million and $15,525 million. The company also expects Adjusted EBITDA to range from $3,705 million to $3,765 million, and Adjusted Diluted Earnings per Share to be between $11.10 and $11.30.

Summarized from source with an LLMView Source

Key figures

15.9%1Y
-5.33%3Y
58.2%5Y

Performance

29.5%1Y
30.7%3Y
33.9%5Y

Volatility

Market cap

44239 M

Market cap (USD)

Daily traded volume (Shares)

242,178

Daily traded volume (Shares)

1 day high/low

246.25 / 239.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-6.33%USD 24.56
Tilray Brands Inc
Tilray Brands Inc Tilray Brands Inc Valor: 42386407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.55%USD 1.80
Shattuck Labs Inc
Shattuck Labs Inc Shattuck Labs Inc Valor: 57260669
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 3.66
Hims & Hers Health Inc
Hims & Hers Health Inc Hims & Hers Health Inc Valor: 59397181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%USD 16.31
Nano-X Imaging Ltd.
Nano-X Imaging Ltd. Nano-X Imaging Ltd. Valor: 56410599
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.73%USD 6.26
KK GNI Group
KK GNI Group KK GNI Group Valor: 3303570
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.38%JPY 2,493.00
Sandoz Group Ltd
Sandoz Group Ltd Sandoz Group Ltd Valor: 124359842
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%CHF 34.78
Stride Inc
Stride Inc Stride Inc Valor: 58406765
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.09%USD 81.92
Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.21%USD 13.87
Biohaven Research Ltd
Biohaven Research Ltd Biohaven Research Ltd Valor: 121902526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.03%USD 39.40